
Leyden Labs has secured €20 million in financing from the European Investment Bank (EIB), supported by HERA Invest under the EU’s InvestEU programme. The funding will support the clinical development of Leyden Labs’ PanFlu nasal spray, an intranasal antibody therapy…










